Therapies targeting Th2 type molecules, IL‐4 and IL‐13, may be expected for refractory erythroderma, although such therapies should be applied to idiopathic erythroderma after malignancies are excluded. This evidence concerns the gene IL4 and exfoliative dermatitis.